DSM pipeline

In line with our strategy, our chosen pipeline candidates have a high potential for positive patient medical impact through innovation.

MCS2101

Registration stage

SuspensionSpheres

Embolisation

Developed for the treatment of benign prostatic hyperplasia through prostatic artery embolization. The product candidate offers important potential advantages over current marketed products, including easy administration, controlled degradation, biocompatibility and potential for enhanced treatment efficacy in patients.

MCS2102

Registration stage

SuspensionSpheres

Embolisation

Developed for use as an embolic agent for the treatment of benign uterine fibroids. The product candidate offers important potential advantages in treatment, including possibility of repeatable administration, biocompatible degradation.

MCS2103

Design verification stage

GelSpheres

Wound care

An easy to use and effective hydrogel for use in advanced wound care. The product is loaded with active substances that in combination are effective in breaking the biofilm on wound surfaces and at for bacterial biofilm-associated wound infection.

MCS2104

Conceptualization stage

GelSpheres

Bone tissue

The project focuses on the development of a new composition for inducing and facilitating repair and re-generation of tissue for use in dental bone tissue engineering incorporating an mRNA molecule that can be used to accelerate normal physiological repair.

MCS2105

Conceptualization stage

SolidSpheres

Drug delivery

The project incorporates cisplatin with the DSM through a lyophilisation technique to generate a solid cake for dissolution and transarterial chemoembolization in the treatment of unresectable hepatocellular carcinoma.